Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes
Sa'ad Abdullahi, Julius Soyinka, Adeniyi Olagunju, Rahman Bolarinwa, Olusola Olarewaju, Moji Bakare-Odunola, Markus Winterberg, Joel Tarning, Andrew Owen & Saye Khoo
There is an increased recognition of the need to identify and quantify the impact of genetic polymorphisms on drug-drug interactions. This study investigated the pharmacogenetics of the pharmacokinetic drug-drug interaction between nevirapine and artemether-lumefantrine in HIV-positive and HIV-negative adult Nigerian subjects. Thirty each of HIV-infected patients on nevirapine-based antiretroviral therapy and HIV-negative volunteers without clinical malaria, but with predetermined CYP2B6 c.516GG and TT genotypes were administered a complete treatment dose of 3-days of artemether-lumefantrine. Rich...
3 citations reported since publication in 2019.
37 views reported since publication in 2019.
These counts follow the
COUNTER Code of Practice,
meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
4 downloads reported since publication in 2019.
These counts follow the
COUNTER Code of Practice,
meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?